FDA Orange Book · active-ingredient family
Elvitegravir
Elvitegravir is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:VITEKTA · NDA 203093
1
Brand (NDA)
0
Generics (ANDA)
6
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VITEKTARLD×2 | GILEAD SCIENCES INC | NDA 203093 | — | Sep 24, 2014 |
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7176220 | Aug 27, 2026 | in 2 mo | SubstanceProductU-257 |
| 7635704 | Oct 26, 2026 | in 4 mo | SubstanceProductU-257 |
| 8981103 | Oct 26, 2026 | in 4 mo | SubstanceProduct |
| 7176220*PED | Feb 27, 2027 | in 8 mo | |
| 7635704*PED | Apr 26, 2027 | in 10 mo | |
| 8981103*PED | Apr 26, 2027 | in 10 mo |
Elvitegravir — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
